<clinical_study>
<study_id>
<org_name>
  Boehringer
</org_name>
<org_full_name>
  Boehringer Ingelheim Pharmaceuticals
</org_full_name>
<org_study_id>
  248.538
</org_study_id>
<nct_id>
  NCT00144300
</nct_id>
</study_id>
<is_fda_regulated>
  Yes
</is_fda_regulated>
<is_section_801>
  Yes
</is_section_801>
<delayed_posting>
  No
</delayed_posting>
<brief_title>
<textblock>
  Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson&apos;s Disease (PD) Patients
</textblock>
</brief_title>
<official_title>
<textblock>
  A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson&apos;s Disease Patients
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Boehringer Ingelheim Pharmaceuticals
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<resp_party_type>
  Sponsor
</resp_party_type>
</resp_party>
<oversight_info>
<regulatory_authority>
  United States: Food and Drug Administration
</regulatory_authority>
</oversight_info>
<brief_summary>
<textblock>
  To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of study at two years.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
  Completed
</status>
<date>
2014-02 
</date>
</status_block>
<start_date>
<date>
  2005-01
</date>
</start_date>
<primary_compl_date
 type="Actual"
>
<date>
  2010-09
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 4
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Diagnostic
</design>
<design>
  Randomized
</design>
<design>
  Open Label
</design>
<design>
  Parallel Assignment
</design>
<design>
  Safety Study
</design>
<number_of_arms>
  2
</number_of_arms>
<primary_outcome>
<measure>
  Expert Panel Overall Assessment Following 2 Years on Drug
</measure>
<time_frame>
  up to 2 years
</time_frame>
<description>
<textblock>
  Expert panel of ophthalmologists assessed retinal deterioration by a review of the components of the comprehensive ophthalmology assessments
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
  Expert Panel Overall Assessment Following 1 Year on Drug
</measure>
<time_frame>
  up to 1 years
</time_frame>
<description>
<textblock>
  Expert panel of ophthalmologists assessed retinal deterioration by a review of the components of the comprehensive ophthalmology assessments
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Hoehn and Yahr Scale at Baseline
</measure>
<time_frame>
  Baseline
</time_frame>
<description>
<textblock>
  This scale is an investigator-completed assessment of the degree of complications arising from Parkinson&apos;s disease. The scale ranges from 0 (No signs) to 5 (Bedridden)
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Hoehn and Yahr Scale at 1 Year
</measure>
<time_frame>
  Up to 1 year
</time_frame>
<description>
<textblock>
  This scale is an investigator-completed assessment of the degree of complications arising from Parkinson&apos;s disease. The scale ranges from 0 (No signs) to 5 (Bedridden)
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Hoehn and Yahr Scale at 2 Years
</measure>
<time_frame>
  Up to 2 years
</time_frame>
<description>
<textblock>
  This scale is an investigator-completed assessment of the degree of complications arising from Parkinson&apos;s disease. The scale ranges from 0 (No signs) to 5 (Bedridden)
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part II, Total Score at Baseline
</measure>
<time_frame>
  Baseline
</time_frame>
<description>
<textblock>
  Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part II, Total Score at 1 Year
</measure>
<time_frame>
  1 year
</time_frame>
<description>
<textblock>
  Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 1 Year
</measure>
<time_frame>
  Baseline, 1 year
</time_frame>
<description>
<textblock>
  Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part II, Total Score at 2 Years
</measure>
<time_frame>
  2 years
</time_frame>
<description>
<textblock>
  Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 2 Years
</measure>
<time_frame>
  Baseline, 2 year
</time_frame>
<description>
<textblock>
  Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part III, Total Score at Baseline
</measure>
<time_frame>
  Baseline
</time_frame>
<description>
<textblock>
  Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part III, Total Score at 1 Year
</measure>
<time_frame>
  1 year
</time_frame>
<description>
<textblock>
  Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 1 Year
</measure>
<time_frame>
  Baseline, 1 year
</time_frame>
<description>
<textblock>
  Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part III, Total Score at 2 Years
</measure>
<time_frame>
  2 years
</time_frame>
<description>
<textblock>
  Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 2 Years
</measure>
<time_frame>
  Baseline, 2 year
</time_frame>
<description>
<textblock>
  Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Parts II and III, Total Score at Baseline
</measure>
<time_frame>
  Baseline
</time_frame>
<description>
<textblock>
  This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Parts II and III, Total Score at 1 Year
</measure>
<time_frame>
  1 year
</time_frame>
<description>
<textblock>
  This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 1 Year
</measure>
<time_frame>
  Baseline, 1 year
</time_frame>
<description>
<textblock>
  This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Parts II and III, Total Score at 2 Years
</measure>
<time_frame>
  2 years
</time_frame>
<description>
<textblock>
  This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 2 Years
</measure>
<time_frame>
  Baseline, 2 year
</time_frame>
<description>
<textblock>
  This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Clinical Abnormal Findings: Clinical Laboratory Evaluations (Biochemistry and Haematology)and Vital Signs
</measure>
<time_frame>
  Screen (Baseline) and final visit (24 months)
</time_frame>
<description>
<textblock>
  Clinical relevant abnormalities for clinical laboratory evaluations Biochemistry and Haematology) and Vital Signs. New abnormal findings or worsening of baseline conditions were reported.
</textblock>
</description>
<safety_issue>
  Yes
</safety_issue>
</secondary_outcome>
<enrollment
 type="Actual"
>
  246
</enrollment>
<condition>
  Parkinson Disease
</condition>
<arm_group>
<arm_group_label>
  Mirapex
</arm_group_label>
<arm_type>
  Active Comparator
</arm_type>
<description>
<textblock>
  Mirapex tablets three times daily (TID) dosing according to manufacturer&apos;s guidelines
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
  Requip
</arm_group_label>
<arm_type>
  Active Comparator
</arm_type>
<description>
<textblock>
  Requip tablets three times daily (TID) dosing according to manufacturer&apos;s guidelines
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Mirapex
</primary_name>
<description>
<textblock>
  Standard marketed product dispensed according to manufacturer&apos;s guidelines
</textblock>
</description>
<arm_group_label>
  Mirapex
</arm_group_label>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Requip
</primary_name>
<description>
<textblock>
  Standard marketed product dispensed according to manufacturer&apos;s guidelines
</textblock>
</description>
<arm_group_label>
  Requip
</arm_group_label>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion criteria
  Diagnosis and main criteria for inclusion.  Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:
  1. Patients with idiopathic Parkinson&apos;s disease of less than 7 years characterized as Stage I-III by the Modified Hoehn and Yahr Scale and with a maximum of 6 months cumulative lifetime exposure to levodopa and/or dopamine agonist.  Patients on current dopamine agonist therapy would require 14-day washout.
  2. Age at least 30 years.
  3. Women of childbearing potential must have a negative serum beta-HCG pregnancy test at the Screen (Baseline) visit and the patient must use adequate contraceptive methods.
  4. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of  all pertinent aspects of the study.
  5. Patients who are willing and able to comply with scheduled visits, treatment plan, and other study procedures.
 
 
  Exclusion criteria
  Main criteria for exclusion. The presence of any of the following would make a patient ineligible for enrollment into the study:  
  1. Previous history of allergic response or complications with any dopaminergic agonist drug
  2. Atypical PD syndromes
  3. History of stereotactic brain surgery
  4. Positive hepatitis B (surface antigen) or hepatitis C (antibody)
  5. Surgery within 180 days of randomization which would negatively impact participation
  6. Folstein&apos;s Mini Mental State Examination (MMSE) score of 24 or less 
  7. History of active epilepsy (seizure) in the past 1 year
  8. Third degree AV block or sick sinus syndrome
  9. Congestive heart failure, Class III or IV
  10. Unstable heart disease such as unstable angina, dysrhythmia, or myocardial infarction in prior 6 months
  11. Symptomatic orthostatic hypotension
  12. Clinically significant liver disease or renal disease
  13. Malignant melanoma or history of previously treated malignant melanoma.
  14. Prohibited medications taken (including any drug known to have potential retino-toxic effects taken in the prior 12 months; neuroleptics taken within prior 6 months, MAO inhibitors except rasagiline or selegiline taken within prior 3 months, beta-blockers taken to treat Parkinson&apos;s disease in the prior 30 days, and Coenzyme Q10 taken within 14 days)
  15. Albinism/Albinoidism of any degree, type or syndrome
  16. History of glaucoma with or without treatment
  17. Inherited or acquired retinopathy such as age-related macular degeneration with visual loss
  18. Sarcoidosis
  19. Diabetes mellitus of any degree even if diet or insulin controlled
  20. Best corrected visual acuity (BCVA) of less than 20/40 by ETDRS
  21. Refractive error of greater than minus-6 diopters
  22. Abnormal electroretinogram (ERG)
  23. Unable to dilate pupils
  24. History of severe eye trauma that might affect the outcome of the study
  25. History of psychosis
  26. Participation in other investigational drug studies or use of investigational drugs within prior 30 days
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Both
</gender>
<minimum_age>
  30 Years
</minimum_age>
<maximum_age>
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Chair
</role>
<name>
  Boehringer Ingelheim
</name>
<affiliation>
<agency>
  Boehringer Ingelheim
</agency>
</affiliation>
</investigator>
<contact>
<name>
  Boehringer Ingelheim Call Center
</name>
<phone>
  1-800-243-0127
</phone>
<phone_ext>
</phone_ext>
<email>
  clintriage.rdg@boehringer-ingelheim.com
</email>
</contact>
<location>
<facility>
<name>
  248.538.00007 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Birmingham
</city>
<state>
  Alabama
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00008 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Little Rock
</city>
<state>
  Arkansas
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00022 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Los Angeles
</city>
<state>
  California
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00021 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Fountain Valley
</city>
<state>
  California
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00001 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  New Haven
</city>
<state>
  Connecticut
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00023 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Tampa
</city>
<state>
  Florida
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00016 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Tampa
</city>
<state>
  Florida
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00002 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Miami
</city>
<state>
  Florida
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00013 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Atlanta
</city>
<state>
  Georgia
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00009 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Augusta
</city>
<state>
  Georgia
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00011 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Chicago
</city>
<state>
  Illinois
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00005 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Baltimore
</city>
<state>
  Maryland
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00014 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Southfield
</city>
<state>
  Michigan
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00020 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  New York
</city>
<state>
  New York
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00015 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  New York
</city>
<state>
  New York
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00010 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  New York
</city>
<state>
  New York
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00012 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Charlotte
</city>
<state>
  North Carolina
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00006 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Philadelphia
</city>
<state>
  Pennsylvania
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00004 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Memphis
</city>
<state>
  Tennessee
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00003 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Houston
</city>
<state>
  Texas
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<location>
<facility>
<name>
  248.538.00017 Boehringer Ingelheim Investigational Site
</name>
<address>
<city>
  Morgantown
</city>
<state>
  West Virginia
</state>
<zip>
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
</location>
<see_also>
<annotation>
<textblock>
</textblock>
</annotation>
<url>
  http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/248/248.538_U11-3426.pdf
</url>
</see_also>
<see_also>
<annotation>
<textblock>
</textblock>
</annotation>
<url>
  http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/248/248.538_literature.pdf
</url>
</see_also>
<initial_release_date>
  2005-09-02
</initial_release_date>
<last_release_date>
2014-02-17 
</last_release_date>
<init_disposition_release_date>
</init_disposition_release_date>
<init_results_release_date>
  2011-09-16
</init_results_release_date>
<clinical_result>
<baseline>
<baselinemeasures>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<dispersionspread>
  9.0
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  58.3
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  9.3
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  57.5
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<dispersionspread>
  8.7
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  59.1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<title>
  Age, Continuous
</title>
<unitofmeasure>
  years
</unitofmeasure>
<othertitle>
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  40
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  23
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  17
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  &lt; 50 years
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  145
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  71
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  74
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  50 to &lt; 65 years
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  51
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  21
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  30
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  65 to &lt; 75 years
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  10
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  6
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  4
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  &gt;= 75 years
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Number
</parametertype>
<title>
  Age, Customized
</title>
<unitofmeasure>
  Participants
</unitofmeasure>
<othertitle>
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  89
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  42
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  47
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Female
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  157
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  79
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  78
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Male
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Number
</parametertype>
<title>
  Gender, Male/Female
</title>
<unitofmeasure>
  Participants
</unitofmeasure>
<othertitle>
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Asian
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  10
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  7
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  3
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Black
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  234
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  113
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  121
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  White
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Number
</parametertype>
<title>
  Race/Ethnicity, Customized
</title>
<unitofmeasure>
  Participants
</unitofmeasure>
<othertitle>
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<dispersionspread>
  10.9
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  171.5
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  9.2
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  171.3
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<dispersionspread>
  12.4
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  171.6
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Measurements collected for 120, 125 participants in Pramipexole, Ropinirole respectively
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<title>
  Study Specific Measure
</title>
<unitofmeasure>
  centimeters
</unitofmeasure>
<othertitle>
  Height
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<dispersionspread>
  18.00
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  82.07
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  17.64
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  81.32
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<dispersionspread>
  18.39
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  82.80
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Measurements collected for 119, 122 participants in Pramipexole, Ropinirole respectively
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<title>
  Study Specific Measure
</title>
<unitofmeasure>
  kilograms
</unitofmeasure>
<othertitle>
  Weight
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<dispersionspread>
  1.46
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  1.13
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  1.15
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  0.97
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<dispersionspread>
  1.70
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  1.29
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<title>
  Study Specific Measure
</title>
<unitofmeasure>
  years
</unitofmeasure>
<othertitle>
  Duration of Parkinson&apos;s disease diagnosis
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 0
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  51
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  28
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  23
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 1
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  30
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  11
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  19
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 1.5
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  142
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  71
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  71
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 2
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  13
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  8
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  5
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 2.5
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  10
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  3
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  7
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 3
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 4
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 5
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  This scale is an investigator-completed assessment of the degree of complications arising from Parkinson&apos;s disease. The scale ranges from 0 (No signs) to 5 (Bedridden)
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<title>
  Study Specific Measure
</title>
<unitofmeasure>
  Participants
</unitofmeasure>
<othertitle>
  Hoehn and Yahr stage
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  95
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  46
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  49
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Does not drink
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  151
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  75
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  76
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Has an average consumption
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Fulfills criteria for Abuse/Dependence
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Number
</parametertype>
<title>
  Study Specific Measure
</title>
<unitofmeasure>
  Participants
</unitofmeasure>
<othertitle>
  Alcohol history
</othertitle>
</baselinemeasure>
</baselinemeasures>
<baselinereportinggroups>
<baselinereportinggroup
 id="Baseline-BaselineRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
</baselinereportinggroup>
<baselinereportinggroup
 id="Baseline-BaselineRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
</baselinereportinggroup>
</baselinereportinggroups>
<totalbaselinereportinggroup
 id="Baseline-TotalBaselineRptGroup"
>
<description>
</description>
<subjectsanalyzed>
  246
</subjectsanalyzed>
<title>
  Total
</title>
</totalbaselinereportinggroup>
</baseline>
<certainagreement>
<otherdetails>
<textblock>
  Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.
</textblock>
</otherdetails>
<pisponsoremployee>
  No
</pisponsoremployee>
<restrictiontype>
  OTHER
</restrictiontype>
<restrictiveagreement>
  Yes
</restrictiveagreement>
</certainagreement>
<lastupdatetimestamp>
2014-02-17T11:23:57-05:00 
</lastupdatetimestamp>
<outcomemeasures>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  34
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  33
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Have retinal deterioration
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  81
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  86
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Have no retinal deterioration
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Expert panel of ophthalmologists assessed retinal deterioration by a review of the components of the comprehensive ophthalmology assessments
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  up to 2 years
</timeframe>
<title>
  Expert Panel Overall Assessment Following 2 Years on Drug
</title>
<unitofmeasure>
  Participants
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Primary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
  0.71
</cilowerlimit>
<cinumsides>
</cinumsides>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
  1.60
</ciupperlimit>
<ciupperlimitnacomment>
</ciupperlimitnacomment>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
</othertypename>
<parametertype>
  Risk Ratio (RR)
</parametertype>
<parametervalue>
  1.07
</parametervalue>
<pvalue>
</pvalue>
<pvaluecomment>
</pvaluecomment>
<statisticalmethod>
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.1-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  115
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.1-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  119
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  FAS LOCF - full analysis set with last observation carry forward
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  28
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  21
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Have retinal deterioration
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  87
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  98
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Have no retinal deterioration
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Expert panel of ophthalmologists assessed retinal deterioration by a review of the components of the comprehensive ophthalmology assessments
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  up to 1 years
</timeframe>
<title>
  Expert Panel Overall Assessment Following 1 Year on Drug
</title>
<unitofmeasure>
  Participants
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.2-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  115
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.2-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  119
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  FAS LOCF - full analysis set with last observation carry forward
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 0
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  28
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  23
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 1
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  11
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  19
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 1.5
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  71
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  71
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 2
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  5
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 2.5
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  3
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  7
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 3
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 4
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 5
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  This scale is an investigator-completed assessment of the degree of complications arising from Parkinson&apos;s disease. The scale ranges from 0 (No signs) to 5 (Bedridden)
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  Baseline
</timeframe>
<title>
  Hoehn and Yahr Scale at Baseline
</title>
<unitofmeasure>
  Participants
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.3-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.3-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  1
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  1
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 0
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  33
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  22
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 1
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  9
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  16
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 1.5
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  70
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  72
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 2
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 2.5
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  6
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 3
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 4
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 5
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  This scale is an investigator-completed assessment of the degree of complications arising from Parkinson&apos;s disease. The scale ranges from 0 (No signs) to 5 (Bedridden)
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  Up to 1 year
</timeframe>
<title>
  Hoehn and Yahr Scale at 1 Year
</title>
<unitofmeasure>
  Participants
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.4-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.4-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  1
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 0
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  27
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  23
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 1
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  6
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  12
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 1.5
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  74
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  73
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 2
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  10
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  10
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 2.5
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  3
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  7
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 3
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 4
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Stage 5
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  This scale is an investigator-completed assessment of the degree of complications arising from Parkinson&apos;s disease. The scale ranges from 0 (No signs) to 5 (Bedridden)
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  Up to 2 years
</timeframe>
<title>
  Hoehn and Yahr Scale at 2 Years
</title>
<unitofmeasure>
  Participants
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.5-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.5-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  3.8
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  4.7
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  9.5
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  Baseline
</timeframe>
<title>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part II, Total Score at Baseline
</title>
<unitofmeasure>
  Score on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.6-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.6-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  4.3
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  7.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  5.0
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8.4
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  1 year
</timeframe>
<title>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part II, Total Score at 1 Year
</title>
<unitofmeasure>
  Score on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.7-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.7-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  3.4
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -1.1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  3.6
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -1.1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  Baseline, 1 year
</timeframe>
<title>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 1 Year
</title>
<unitofmeasure>
  Score on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.8-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.8-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.9-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  4.6
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8.4
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.9-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  5.2
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  9.3
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  2 years
</timeframe>
<title>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part II, Total Score at 2 Years
</title>
<unitofmeasure>
  Score on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.9-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.9-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.10-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  3.7
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0.4
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.10-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  4.0
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -0.2
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  Baseline, 2 year
</timeframe>
<title>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 2 Years
</title>
<unitofmeasure>
  Score on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.10-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.10-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.11-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  9.3
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  20.7
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.11-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  10.2
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  22.4
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  Baseline
</timeframe>
<title>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part III, Total Score at Baseline
</title>
<unitofmeasure>
  Score on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.11-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.11-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.12-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  9.3
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  17.7
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.12-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  10.9
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  19.8
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  1 year
</timeframe>
<title>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part III, Total Score at 1 Year
</title>
<unitofmeasure>
  Score on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.12-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.12-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.13-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  7.2
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -3.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.13-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  6.1
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -2.6
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  Baseline, 1 year
</timeframe>
<title>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 1 Year
</title>
<unitofmeasure>
  Score on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.13-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.13-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.14-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  9.9
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  19.7
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.14-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  10.3
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  20.9
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  2 years
</timeframe>
<title>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part III, Total Score at 2 Years
</title>
<unitofmeasure>
  Score on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.14-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.14-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.15-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  7.9
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -1.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.15-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  7.7
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -1.5
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  Baseline, 2 year
</timeframe>
<title>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 2 Years
</title>
<unitofmeasure>
  Score on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.15-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.15-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.16-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  11.6
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  28.8
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.16-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  13.4
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  31.9
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  Baseline
</timeframe>
<title>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Parts II and III, Total Score at Baseline
</title>
<unitofmeasure>
  Score on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.16-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.16-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.17-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  11.8
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  24.7
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.17-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  14.5
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  28.2
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  1 year
</timeframe>
<title>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Parts II and III, Total Score at 1 Year
</title>
<unitofmeasure>
  Score on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.17-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.17-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.18-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  8.9
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -4.1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.18-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  8.2
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -3.7
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  Baseline, 1 year
</timeframe>
<title>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 1 Year
</title>
<unitofmeasure>
  Score on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.18-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.18-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.19-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  12.9
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  28.1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.19-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  14.1
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  30.2
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  2 years
</timeframe>
<title>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Parts II and III, Total Score at 2 Years
</title>
<unitofmeasure>
  Score on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.19-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.19-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.20-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  10.1
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -0.7
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.20-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  10.5
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -1.7
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  Baseline, 2 year
</timeframe>
<title>
  Unified Parkinson&apos;s Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 2 Years
</title>
<unitofmeasure>
  Score on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.20-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  121
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.20-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  125
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  TS - treated set
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.21-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.21-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Haematocrit - Decrease
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.21-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.21-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  5
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Haemoglobin - Decrease
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.21-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  4
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.21-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Eosinophils - Increase
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.21-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.21-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Phosphate - Decrease
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.21-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.21-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Calcium - Increase
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.21-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  4
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.21-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Glucose - Decrease
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Clinical relevant abnormalities for clinical laboratory evaluations Biochemistry and Haematology) and Vital Signs. New abnormal findings or worsening of baseline conditions were reported.
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  Screen (Baseline) and final visit (24 months)
</timeframe>
<title>
  Clinical Abnormal Findings: Clinical Laboratory Evaluations (Biochemistry and Haematology)and Vital Signs
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<anticipatedresultpostingdate>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.21-OutcomeRptGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  109
</subjectsanalyzed>
<title>
  Pramipexole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.21-OutcomeRptGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<subjectsanalyzed>
  110
</subjectsanalyzed>
<title>
  Ropinirole
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
TSlab -  treated  set  with non-missing laboratory evaluations 
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  Yes
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
</outcomemeasures>
<participantflow>
<participantflowgroups>
<flowgroup
 id="ParticipantFlow-ParticipantFlowGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<title>
  Pramipexole
</title>
</flowgroup>
<flowgroup
 id="ParticipantFlow-ParticipantFlowGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<title>
  Ropinirole
</title>
</flowgroup>
</participantflowgroups>
<periods>
<period>
<completedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  92
</subjectsachieve>
</milestoneachievement>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  97
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</completedmilestone>
<dropwithdrawreasons>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  18
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  16
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Adverse Event
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  3
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Protocol Violation
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  3
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  0
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Lost to Follow-up
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  6
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  6
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Withdrawal by Subject
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  3
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
  Other reason (not specified)
</otherreasonname>
<reasontype>
  Other
</reasontype>
</dropwithdrawreason>
</dropwithdrawreasons>
<milestones>
</milestones>
<otherparticipantflowdetails>
<otherdetail>
<numbernotcompleted>
  29
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
</otherdetail>
<otherdetail>
<numbernotcompleted>
  28
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
</otherdetail>
</otherparticipantflowdetails>
<startedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  121
</subjectsachieve>
</milestoneachievement>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  125
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</startedmilestone>
<title>
  Overall Study
</title>
</period>
</periods>
<preassignmentdescription>
</preassignmentdescription>
<recruitmentdetails>
</recruitmentdetails>
</participantflow>
<pointofcontact>
<email>
  clintriage.rdg@boehringer-ingelheim.com
</email>
<organizationname>
  Boehringer Ingelheim Pharmaceuticals
</organizationname>
<phoneextension>
</phoneextension>
<phonenumber>
  1-800-243-0127
</phonenumber>
<title>
  Boehringer Ingelheim Call Center
</title>
</pointofcontact>
<recordstatus>
  RELEASED
</recordstatus>
<reportedevents>
<assessmenttype>
</assessmenttype>
<frequencyreportingthreshold>
  5
</frequencyreportingthreshold>
<frequentadverseevents>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Eye disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Vision blurred
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Abdominal pain upper
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  18
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  26
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Constipation
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Diarrhoea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Dry mouth
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Dyspepsia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  8
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Dysphagia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  31
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  59
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Nausea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  12
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Vomiting
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Chest pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  27
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  25
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Fatigue
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  22
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  18
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Oedema peripheral
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  17
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  16
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Nasopharyngitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Sinusitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  12
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  13
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Upper respiratory tract infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Urinary tract infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  12
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Arthralgia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  17
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Back pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Muscle spasms
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Musculoskeletal pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  8
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Myalgia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  12
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  13
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Pain in extremity
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  27
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  35
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Dizziness
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Dizziness postural
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  15
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  27
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Headache
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Hypoaesthesia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  10
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Paraesthesia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  53
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  71
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Somnolence
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  11
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  16
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Sudden onset of sleep
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  8
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Psychiatric disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Abnormal dreams
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  10
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  14
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Psychiatric disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Anxiety
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  8
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  15
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Psychiatric disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Depression
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  19
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  27
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Psychiatric disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Insomnia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  10
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Psychiatric disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Sleep disorder
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Erectile dysfunction
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  8
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Cough
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  10
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Rash
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  10
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Hypertension
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  10
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  14
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Orthostatic hypotension
</term>
</frequentevent>
</frequentadverseevents>
<interventiongroups>
<interventiongroup
 id="ReportedEvents-InterventionGroup.1"
>
<description>
<textblock>
  Flexible: 0.125 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<numsubjectsfrequentevents>
  97
</numsubjectsfrequentevents>
<numsubjectsseriousevents>
  22
</numsubjectsseriousevents>
<partatriskfrequentevents>
  121
</partatriskfrequentevents>
<partatriskseriousevents>
  121
</partatriskseriousevents>
<title>
  Pramipexole
</title>
</interventiongroup>
<interventiongroup
 id="ReportedEvents-InterventionGroup.2"
>
<description>
<textblock>
  Flexible: 0.25 mg 3 times daily up to maximum tolerated
</textblock>
</description>
<numsubjectsfrequentevents>
  101
</numsubjectsfrequentevents>
<numsubjectsseriousevents>
  21
</numsubjectsseriousevents>
<partatriskfrequentevents>
  125
</partatriskfrequentevents>
<partatriskseriousevents>
  125
</partatriskseriousevents>
<title>
  Ropinirole
</title>
</interventiongroup>
</interventiongroups>
<notes>
</notes>
<seriousadverseevents>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Anaemia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Haemorrhagic anaemia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Acute myocardial infarction
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Atrial fibrillation
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Bradycardia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Cardiac failure congestive
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Coronary artery occlusion
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Abdominal pain lower
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Colitis ischaemic
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Rectal haemorrhage
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Small intestinal obstruction
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Chest discomfort
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Hepatobiliary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Biliary colic
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Hepatobiliary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Biliary dyskinesia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Hepatobiliary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Cholelithiasis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Immune system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Hypersensitivity
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Appendicitis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Enterocolitis infectious
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Fall
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Femur fracture
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Hand fracture
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Hip fracture
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Incisional hernia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Jaw fracture
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Lower limb fracture
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Post procedural haemorrhage
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Pubis fracture
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Rib fracture
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Road traffic accident
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Stab wound
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Tibia fracture
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Fluid overload
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Arthralgia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Arthritis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Back pain
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Groin pain
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Lumbar spinal stenosis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Osteoarthritis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Basal cell carcinoma
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Malignant melanoma
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Malignant melanoma in situ
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Ovarian granulosa-theca cell tumour
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Prostate cancer
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Small cell lung cancer stage unspecified
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Squamous cell carcinoma
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Squamous cell carcinoma of skin
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Transitional cell carcinoma
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Uterine leiomyoma
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Brain mass
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Loss of consciousness
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Syncope
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Transient global amnesia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Psychiatric disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Delirium
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Psychiatric disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Delusion
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Psychiatric disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Hallucination, visual
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Psychiatric disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Psychotic disorder
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Urinary incontinence
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Cystocele
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Endometrial hyperplasia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Hyperthecosis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Prostatomegaly
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Uterine haemorrhage
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Uterine polyp
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Pulmonary embolism
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  121
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  125
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA Version 13.1
</sourcevocabulary>
<term>
  Thrombosis
</term>
</seriousevent>
</seriousadverseevents>
<sourcevocabulary>
</sourcevocabulary>
<timeframe>
  up to 24 months
</timeframe>
</reportedevents>
</clinical_result>
</clinical_study>
